HK1244802A1 - 用於治療疾病的稠合雙環化合物 - Google Patents
用於治療疾病的稠合雙環化合物Info
- Publication number
- HK1244802A1 HK1244802A1 HK18104188.4A HK18104188A HK1244802A1 HK 1244802 A1 HK1244802 A1 HK 1244802A1 HK 18104188 A HK18104188 A HK 18104188A HK 1244802 A1 HK1244802 A1 HK 1244802A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- disease
- treatment
- fused bicyclic
- bicyclic compounds
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462083031P | 2014-11-21 | 2014-11-21 | |
PCT/US2015/062017 WO2016081918A1 (en) | 2014-11-21 | 2015-11-20 | Fused bicyclic compounds for the treatment of disease |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1244802A1 true HK1244802A1 (zh) | 2018-08-17 |
Family
ID=56014622
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18104188.4A HK1244802A1 (zh) | 2014-11-21 | 2018-03-27 | 用於治療疾病的稠合雙環化合物 |
Country Status (18)
Country | Link |
---|---|
US (4) | US10233187B2 (zh) |
EP (1) | EP3221321B1 (zh) |
JP (3) | JP7224102B2 (zh) |
KR (1) | KR20170117020A (zh) |
CN (2) | CN107207513B (zh) |
AU (2) | AU2015349687B2 (zh) |
CA (1) | CA2968434A1 (zh) |
CL (1) | CL2017001289A1 (zh) |
CO (1) | CO2017005784A2 (zh) |
ES (1) | ES2911293T3 (zh) |
HK (1) | HK1244802A1 (zh) |
IL (1) | IL252309B (zh) |
MX (1) | MX370480B (zh) |
MY (1) | MY192927A (zh) |
RU (1) | RU2706007C2 (zh) |
SA (1) | SA517381566B1 (zh) |
SG (2) | SG10202010386PA (zh) |
WO (1) | WO2016081918A1 (zh) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
SG11201700777VA (en) | 2014-08-04 | 2017-02-27 | Nuevolution As | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
MX370480B (es) * | 2014-11-21 | 2019-12-16 | Akarna Therapeutics Ltd | Compuestos bicíclicos fusionados para el tratamiento de enfermedades. |
SG10201908881PA (en) * | 2015-03-26 | 2019-11-28 | Akarna Therapeutics Ltd | Fused bicyclic compounds for the treatment of disease |
US20200397798A1 (en) * | 2016-05-25 | 2020-12-24 | Akarna Therapeutics, Ltd. | Combination therapies with farnesoid x receptor (fxr) modulators |
EP3730487B1 (en) | 2016-06-13 | 2022-04-27 | Gilead Sciences, Inc. | Azetidine derivatives as fxr (nr1h4) modulators |
CA2968836A1 (en) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
EP4122464B1 (en) | 2017-03-28 | 2024-05-15 | Gilead Sciences, Inc. | Therapeutic combinations for treating liver diseases |
AU2018275674A1 (en) * | 2017-06-02 | 2020-01-16 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds |
EP4360632A2 (en) | 2019-01-15 | 2024-05-01 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
AU2020225225B2 (en) | 2019-02-19 | 2022-12-22 | Gilead Sciences, Inc. | Solid forms of FXR agonists |
CN111825653A (zh) * | 2019-04-19 | 2020-10-27 | 安道麦马克西姆有限公司 | 取代吡唑类化合物的制备及其作为邻氨基苯甲酰胺前体的用途 |
KR20220038368A (ko) | 2019-07-23 | 2022-03-28 | 노파르티스 아게 | Fxr 작용제를 이용하는 간 질환의 병용 치료 |
CA3142904A1 (en) | 2019-07-23 | 2021-01-28 | Novartis Ag | Treatment comprising fxr agonists |
JOP20220057A1 (ar) | 2019-09-03 | 2023-01-30 | Novartis Ag | علاج أمراض أو اضطرابات الكبد تشتمل على مضادات مستقبل actrii |
CN114401745A (zh) | 2019-09-19 | 2022-04-26 | 诺华股份有限公司 | 包含fxr激动剂的治疗 |
US20220331341A1 (en) | 2019-09-30 | 2022-10-20 | Novartis Ag | Treatment comprising the use of fxr agonists |
MX2022007265A (es) | 2019-12-20 | 2022-09-09 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
CA3164941A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Combination treatment of liver diseases using integrin inhibitors |
JP2023519605A (ja) | 2020-03-31 | 2023-05-11 | ヌエヴォリューション・アクティーゼルスカブ | 核内受容体に対して活性な化合物 |
WO2021198955A1 (en) | 2020-03-31 | 2021-10-07 | Nuevolution A/S | Compounds active towards nuclear receptors |
AR123313A1 (es) * | 2020-08-24 | 2022-11-16 | Adama Makhteshim Ltd | Proceso para la preparación de pirazoles sustituidos |
WO2022101853A1 (en) | 2020-11-16 | 2022-05-19 | Novartis Ag | Method of determining liver fibrosis |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7595311B2 (en) * | 2002-05-24 | 2009-09-29 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
BRPI0412262A (pt) | 2003-07-23 | 2006-09-19 | X Ceptor Therapeutics Inc | derivados de azepina como agentes farmacêuticos |
BRPI0414541B8 (pt) | 2003-09-17 | 2021-05-25 | Janssen Pharmaceutica Nv | compostos heterocíclicos fundidos tendo atividade de modulação de receptor de serotonina, método de preparação de compostos intermediários |
US20090137554A1 (en) * | 2007-10-22 | 2009-05-28 | Wyeth | 1,4,5,6-TETRAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY |
US20090215748A1 (en) * | 2007-12-20 | 2009-08-27 | Wyeth | FXR agonists for treating vitamin D associated diseases |
JP2012503654A (ja) | 2008-09-26 | 2012-02-09 | ワイス・エルエルシー | 1,2,3,6−テトラヒドロアゼピノ[4,5−b]インドール−5−カルボキシレート核内受容体阻害剤 |
US8252826B2 (en) | 2010-03-24 | 2012-08-28 | Hoffmann-La Roche Inc. | Cyclopentyl- and cycloheptylpyrazoles |
MX370480B (es) * | 2014-11-21 | 2019-12-16 | Akarna Therapeutics Ltd | Compuestos bicíclicos fusionados para el tratamiento de enfermedades. |
CA3025326A1 (en) * | 2016-05-25 | 2017-11-30 | Benjamin Anthony PRATT | Fused bicyclic compounds for the treatment of disease |
-
2015
- 2015-11-20 MX MX2017006694A patent/MX370480B/es active IP Right Grant
- 2015-11-20 CN CN201580073351.8A patent/CN107207513B/zh active Active
- 2015-11-20 CN CN202010634386.7A patent/CN111662297A/zh active Pending
- 2015-11-20 AU AU2015349687A patent/AU2015349687B2/en active Active
- 2015-11-20 MY MYPI2017701793A patent/MY192927A/en unknown
- 2015-11-20 JP JP2017545870A patent/JP7224102B2/ja active Active
- 2015-11-20 EP EP15861717.5A patent/EP3221321B1/en active Active
- 2015-11-20 SG SG10202010386PA patent/SG10202010386PA/en unknown
- 2015-11-20 KR KR1020177016606A patent/KR20170117020A/ko not_active Application Discontinuation
- 2015-11-20 CA CA2968434A patent/CA2968434A1/en active Pending
- 2015-11-20 RU RU2017121588A patent/RU2706007C2/ru active
- 2015-11-20 WO PCT/US2015/062017 patent/WO2016081918A1/en active Application Filing
- 2015-11-20 SG SG11201703953WA patent/SG11201703953WA/en unknown
- 2015-11-20 ES ES15861717T patent/ES2911293T3/es active Active
-
2017
- 2017-05-16 IL IL252309A patent/IL252309B/en active IP Right Grant
- 2017-05-19 CL CL2017001289A patent/CL2017001289A1/es unknown
- 2017-05-19 US US15/599,647 patent/US10233187B2/en active Active
- 2017-05-20 SA SA517381566A patent/SA517381566B1/ar unknown
- 2017-06-12 CO CONC2017/0005784A patent/CO2017005784A2/es unknown
-
2018
- 2018-03-27 HK HK18104188.4A patent/HK1244802A1/zh unknown
-
2019
- 2019-03-15 US US16/354,879 patent/US20190308977A1/en not_active Abandoned
-
2020
- 2020-07-22 JP JP2020125592A patent/JP2021011482A/ja active Pending
- 2020-09-18 US US17/025,724 patent/US20210147426A1/en not_active Abandoned
- 2020-10-08 AU AU2020250270A patent/AU2020250270B2/en active Active
-
2022
- 2022-09-16 US US17/932,876 patent/US20230183247A1/en active Pending
- 2022-10-26 JP JP2022171339A patent/JP2023011731A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1244802A1 (zh) | 用於治療疾病的稠合雙環化合物 | |
HK1245795A1 (zh) | 用於治療疾病的稠合雙環化合物 | |
HK1244276A1 (zh) | 用於治療hiv的稠合嘧啶化合物 | |
EP3227330C0 (en) | TDP-43 BINDING POLYPEPTIDES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | |
HK1256795A1 (zh) | 可用於治療自身免疫疾病的二吡唑基衍生物 | |
HRP20181672T1 (hr) | Kondenzirani bicklički (hetero)aromatski spojevi pogodni za liječenje karcinoma | |
HK1249756A1 (zh) | 用於治療疾病的稠合雙環化合物 | |
IL250613A0 (en) | Derivatives of bicyclic compounds | |
RS61504B1 (sr) | Jedinjenja heteroarila za lečenje oftalmičkih bolesti | |
IL259297A (en) | Heterocyclic compounds for the treatment of disease | |
IL263177A (en) | Fused bicyclic compounds for the treatment of disease | |
ZA201704589B (en) | Compounds for the treatment of cancer |